These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Urticarial reactions to insulin]. MUSSO E; GOLAY M Dermatologica; 1954; 108(4-6):274-8. PubMed ID: 13190907 [No Abstract] [Full Text] [Related]
6. Severe adverse cutaneous reaction to insulin due to cresol sensitivity. Rajpar SF; Foulds IS; Abdullah A; Maheshwari M Contact Dermatitis; 2006 Aug; 55(2):119-20. PubMed ID: 16930241 [TBL] [Abstract][Full Text] [Related]
7. Severe insulin allergy after percutaneous transluminal coronary angioplasty. Wang C; Ding ZY; Shu SQ; Liu Y; Chen YC; Ran XW; An ZM; Tian HM; Tong NW; Li XJ; Yu YR Clin Ther; 2009 Mar; 31(3):569-74. PubMed ID: 19393846 [TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse drug reactions seen at a university hospital department of dermatology. Borch JE; Andersen KE; Bindslev-Jensen C Acta Derm Venereol; 2006; 86(6):523-7. PubMed ID: 17106600 [TBL] [Abstract][Full Text] [Related]
9. [Insulin allergy: background, diagnosis and treatment]. Wonders J; Eekhoff EM; Heine R; Bruynzeel DP; Rustemeyer T Ned Tijdschr Geneeskd; 2005 Dec; 149(50):2783-8. PubMed ID: 16385830 [TBL] [Abstract][Full Text] [Related]
10. [Insulin analogs under discussion. How safe are designer hormones?]. MMW Fortschr Med; 2001 Nov; 143(47):65. PubMed ID: 11791372 [No Abstract] [Full Text] [Related]
11. [Practice tips for modern insulin therapy. "Bed time insulins without adverse morning aftereffect"]. Bottermann P MMW Fortschr Med; 1999 Dec; 141(48):40-2. PubMed ID: 10728299 [No Abstract] [Full Text] [Related]
12. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages. Prescrire Int; 2006 Oct; 15(85):163-7. PubMed ID: 17121210 [TBL] [Abstract][Full Text] [Related]
13. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study. Gao Y; Guo XH; Vaz JA; Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806 [TBL] [Abstract][Full Text] [Related]
15. Lispro insulin-induced lipoatrophy: a new case. Al-Khenaizan S; Al Thubaiti M; Al Alwan I Pediatr Diabetes; 2007 Dec; 8(6):393-6. PubMed ID: 18036067 [TBL] [Abstract][Full Text] [Related]
16. Hypoglycemia in the intensive care unit. Mechanick JI; Handelsman Y; Bloomgarden ZT Curr Opin Clin Nutr Metab Care; 2007 Mar; 10(2):193-6. PubMed ID: 17285009 [TBL] [Abstract][Full Text] [Related]
17. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study. Yenigun M; Honka M Int J Clin Pract; 2009 Mar; 63(3):425-32. PubMed ID: 19222627 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628 [TBL] [Abstract][Full Text] [Related]
19. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Hoogma RP; Schumicki D Horm Metab Res; 2006 Jun; 38(6):429-33. PubMed ID: 16823727 [TBL] [Abstract][Full Text] [Related]
20. Inhaled human insulin: new drug. No short-term advantages, too many unknowns in the long term. Prescrire Int; 2006 Dec; 15(86):203-9. PubMed ID: 17165235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]